1 Min Read
* IMMUNOMEDICS ANNOUNCES PROMISING DATA OF SACITUZUMAB GOVITECAN IN ESTROGEN RECEPTOR-POSITIVE METASTATIC BREAST CANCER Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.